SBIR/STTR Research Award

Intraosseous Auto-injector Delivery of Antidotes

Award identifier d927bb59763e206102d311054239b93a5b9d88863d36ffd8aa03c1ba9af19a3bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,292

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Resuscitation Solution, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Recent events have brought a clear message to America: both our military and civilian sectors must be ready to deal with mass casualties of chemical and biological agents. In order to provide a more rapidly effective means to treat medical emergencies, Resuscitation Solutions, Inc. has developed FirstMed, an intraosseous auto-injector for self- or buddy-administration of emergency antidotes and drugs. The military and civilian approach to emergency treatment of nerve gas toxicity is the use of small dose intramuscular (IM) auto-injectors as standard of care for rapid self-aid or buddy aid of nerve gas antidotes. This proposal extends this concept to provide a more effective auto-injector with near immediate vascular entry. Vascular uptake of IM injections is likely to be further delayed under conditions of circulatory shock, when hypoperfusion of muscle delays drug uptake. Our research will be the first testing and use of the innovative FirstMed injector for intraosseous (IO) auto-injector administration of time-critical nerve gas antidotes. We hypothesize that IO delivery of nerve gas antidote provides a significant time advantage over the IM route, in the ability to more rapidly achieve therapeutic blood levels after injection and that 10 injector treatment followed by IM injector treatment provides both immediate and sustained circulatory delivery of nerve gas antidote. We address our hypothesis with two specific aims: 1) measure relative pharmacokinetics of pralidoxime (2-PAM-CI) following IM or IO injection or combined IO injection followed by IM injection in healthy anesthetized normovolemic pigs. 2) evaluate the changes in pharmacokinetics of 2-PAM-CL following IM or IO injection in the compromised circulation of hypovolemic pigs. Intraosseous auto-injector administration of antidotes into red bone marrow is likely to result in significantly better clinical outcomes in severely debilitated victims of chemical agents, organophosphate poisoning or severe anaphylactic reactions. FirstMed IO auto-injectors may provide the most effective initial step in therapy for treatment of soldiers and civilians in the event of exposure to chemical toxins due to weapons or terrorists.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.